Abstract
Motivated by the challenge of risk assessment in a heterogeneous population and guided by advances in our knowledge of the pathobiology of cardiovascular diseases (CVD), basic and clinical scientists have maintained substantial interest in the development and application of novel biomarkers for risk stratification of CVD. In particular, strategies to identify and combine multiple biomarkers, which may reflect diverse pathobiological contributors to the onset and complications of CVD, have been arising as an approach to improve more effectively the risk assessment and target therapy. Moreover, comparative evaluations of novel markers are necessary to estimate these candidates for integration into present and future strategies. In this review we consider the recent in-depth knowledge and advances with the use of systemic biomarkers in the area of CVD with special attention on inflammatory markers and those that can predict an individual arteriosclerotic disease stage.
Keywords: Cardiovascular disease, systemic biomarkers, diagnosis, prognosis, atherosclerosis, risk prediction, risk factors, coronary heart disease, inflammation
Current Molecular Medicine
Title: Novel Systemic Cardiovascular Disease Biomarkers
Volume: 10 Issue: 2
Author(s): G. A. Bonaterra, S. Zugel and R. Kinscherf
Affiliation:
Keywords: Cardiovascular disease, systemic biomarkers, diagnosis, prognosis, atherosclerosis, risk prediction, risk factors, coronary heart disease, inflammation
Abstract: Motivated by the challenge of risk assessment in a heterogeneous population and guided by advances in our knowledge of the pathobiology of cardiovascular diseases (CVD), basic and clinical scientists have maintained substantial interest in the development and application of novel biomarkers for risk stratification of CVD. In particular, strategies to identify and combine multiple biomarkers, which may reflect diverse pathobiological contributors to the onset and complications of CVD, have been arising as an approach to improve more effectively the risk assessment and target therapy. Moreover, comparative evaluations of novel markers are necessary to estimate these candidates for integration into present and future strategies. In this review we consider the recent in-depth knowledge and advances with the use of systemic biomarkers in the area of CVD with special attention on inflammatory markers and those that can predict an individual arteriosclerotic disease stage.
Export Options
About this article
Cite this article as:
Bonaterra A. G., Zugel S. and Kinscherf R., Novel Systemic Cardiovascular Disease Biomarkers, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963330
DOI https://dx.doi.org/10.2174/156652410790963330 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MRI Contrast Agents: Current Status and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options
Current Pharmaceutical Design Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology Advances in Catheter Ablation: Atrial Fibrillation Ablation in Patients With Mitral Mechanical Prosthetic Valve
Current Cardiology Reviews HIV Infection, Antiretroviral Therapy Initiation and Longitudinal Changes in Biomarkers of Organ Function
Current HIV Research Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience
Current Alzheimer Research Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer
Reviews on Recent Clinical Trials Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study
Current Drug Discovery Technologies Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Pharmacologic Treatment for Prehypertension: To Treat or Not to Treat?
Recent Patents on Cardiovascular Drug Discovery Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Interatrial Block in the Modern Era
Current Cardiology Reviews The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence
Current Vascular Pharmacology Recent Patent in Controlled Porosity Osmotic Pump
Recent Patents on Drug Delivery & Formulation